VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
Last update: 7 hours ago463.48
-7.39 (-1.57%)
| Previous Close | 470.87 |
| Open | 469.85 |
| Volume | 2,081,183 |
| Avg. Volume (3M) | 1,403,291 |
| Market Cap | 118,831,947,776 |
| Price / Earnings (TTM) | 32.59 |
| Price / Earnings (Forward) | 24.10 |
| Price / Sales | 10.37 |
| Price / Book | 6.89 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 606.00 (Barclays, 30.75%) | Buy |
| Median | 545.50 (17.70%) | |
| Low | 515.00 (Wells Fargo, 11.12%) | Buy |
| Average | 547.38 (18.10%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 464.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 606.00 (30.75%) | Buy | 477.91 |
| UBS | 26 Jan 2026 | 545.00 (17.59%) | Buy | 476.84 |
| 07 Jan 2026 | 535.00 (15.43%) | Buy | 484.15 | |
| Evercore ISI Group | 23 Jan 2026 | 530.00 (14.35%) | Buy | 468.41 |
| RBC Capital | 22 Jan 2026 | 546.00 (17.80%) | Buy | 467.35 |
| Wolfe Research | 06 Jan 2026 | 548.00 (18.24%) | Buy | 468.38 |
| Leerink Partners | 29 Dec 2025 | 525.00 (13.27%) | Buy | 459.78 |
| Wells Fargo | 10 Dec 2025 | 515.00 (11.12%) | Buy | 444.64 |
| Morgan Stanley | 05 Dec 2025 | 564.00 (21.69%) | Buy | 455.48 |
| 03 Dec 2025 | 516.00 (11.33%) | Buy | 463.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |